It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

Mesoblast Limited (Nasdaq: MESO; ASX:MSB), a leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a capital raising of US$90 million¹ (A$138 million) via a private placement of 43 million shares to existing and new institutional investors at a price of A$3.20 per share. A significant portion of the net proceeds will be used to scale-up manufacturing of the Company’s lead product candidate remestemcel-L for the treatment of critically ill patients suffering with diseases caused by cytokine release syndromes associated with high mortality, particularly COVID-19 acute respiratory distress syndrome (ARDS). A randomized controlled Phase 2/3 trial in up to 300 patients evaluating whether remestemcel-L can reduce the high mortality in COVID-19 patients with moderate/severe ARDS is actively enrolling in up to 30 sites in the United States.

NEW YORK, May 06, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the first patients have.

NEW YORK, May 26, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in 240 patients with acute respiratory distress syndrome (ARDS) caused by coronavirus infection (COVID-19). This multi-center Phase 2/3 trial will be conducted as a public-private partnership in a collaboration with the Cardiothoracic Surgical Trials Network (CTSN), which was established by the United States National Institutes of Health’s National Heart, Lung and Blood Institute (NHLBI) as a flexible platform for conducting collaborative trials. Mesoblast holds an Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) for use of remestemcel-L in the treatment of patients with COVID-19 ARDS, and will provide investigational product for the trial.

Key points:  83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated with two.

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors...

Shares of Mesoblast (NASDAQ: MESO) rose as much as 27.2% today after the company announced the pricing of an offering of common stock. The stem cell developer will issue up to 43 million shares of common stock at AUD$3.20 apiece on the Australian Securities Exchange (ASX). The Sydney Morning Herald reported that Mesoblast had to push back "on demand from both new and existing institutional investors."

The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron

NEW YORK, April 17, 2020 -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB) today announced that results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic mesenchymal stem cell therapy remestemcel-L provides a survival benefit in moderate/severe acute respiratory distress syndrome (ARDS) due to COVID-19 has commenced enrollment. More than 20 medical centers across the United States will participate in the trial which is expected to complete enrollment within three to four months, with interim analyses planned which could result in stopping the trial early for efficacy or futility.

NEW YORK, March 30, 2020 -- Results from a sub-study of 70 patients with end-stage ischemic heart failure and a Left Ventricular Assist Device (LVAD), of 159 randomized.

The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.

The Israeli company reported its placenta-based treatment seemed to reduce complications in a small study Continue reading...

NEW YORK, April 01, 2020 -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the United States.

Key points:  Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy, publishes three.

Mesoblast's (MESO) shares are cooling off today. After skyrocketing 140% on Friday, the Australian biotech fell 25% today.The lift off came following the release of strong preliminary data concerning its stem cell candidate for treating COVID-19 patients.Mesoblast’s allogeneic mesenchymal stem cell candidate remestemcel-L showed exceptional promise when given to 12 ventilator dependent COVID-19 patients with acute respiratory distress syndrome (ARDS).The 12 patients were given two intravenous infusions of remestemcel-L and within the first five days, ten patients (83%) survived, while nine patients (75%) were removed off ventilator support after a median follow up of ten days. Seven of the patients (58%) were discharged from the hospital.Although a 12 people study is rather small, to put the results into context, in a large study consisting of 5700 patients of ventilator dependent COVID-19 patients, conducted at another New York hospital, the mortality rate was 88%.Additionally, only 9% of COVID-19 patients who received standard-of-care treatment in another hospital, were able to come off ventilator support in a 4103-patient study published in medRxiv in early April.H.C. Wainwright’s Swayampakula Ramakanth believes the early results are encouraging and indicate promise for the success of Mesoblast’s Phase 2/3 study of remestemcel-L in patients with COVID-19 associated ARDS. The study should commence shortly, with enrollment expected to be finalized over the next 3 months. The trial will have the 28-day mortality rate as its primary endpoint.“We are encouraged by these early results and believe that it bodes well for the success of Mesoblast’s Phase 2/3 study of remestemcel-L in patients with COVID-19 associated ARDS. Recall, the Phase 2/3 study is expected to be a 1:1 randomized, placebocontrolled trial in 240 COVID-19 patients with ARDS with a primary endpoint of 28-day mortality rate. Secondary endpoints could include safety, days without ventilator, and survival at different time points. The study is expected to initiate imminently, and management expects to complete patient enrollment in three months. An interim readout is expected at the completion of enrollment of one third of the planned study population. We believe the use of remestemcel-L for the treatment of ARDS could become a significant upside for the company,” said Ramakanth.Ramakanth reiterated a Buy on Mesoblast along with a $14 price target, which implies a potential upside of 21% from current levels. (To Ramakanth’s track record, click here)Only two fellow analysts have published reviews of Mesoblast over the last 3 months, both recommending the stock a Buy. Accordingly, MESO has a Strong Buy consensus rating. The average price target, at $15.00, is a bit more bullish than Ramakanth's – a 29% for Mesoblast shares. (See Mesoblast stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

NEW YORK, April 06, 2020 -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it has received.

NEW YORK, May 27, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial,.

The Australian stem-cell therapy developer presented promising data for COVID-19 patients days ago, but investors took some gains off the table today.